The influence of interleukin-6 gene polymorphism on omega-3 fatty acid effect in type 2 diabetic patients

Abstract

Aim The aim of this study was to examine the effects of omega-3 fatty acids on novel cardiovascular risk factors in relation to +174 G>C interleukin-6 gene (IL6) single nucleotide polymorphism (SNP). Methods A total of 61 patients (M/F: 34/27; age 53.9±1.2 yrs; BMI 32.68±0.77kg/m 2 ; HbA1С 7.06±0.18%; FBG 8.00±0.28mmol/L) with Type 2 diabetes mellitus (T2D) were treated with omega-3 fatty acids (1-g capsule containing at least 900mg of ethyl esters of eicosapentaenoic and docosahexaenoic acids, daily) for 12 weeks without changing any of their previous medications. In all the +174 G>C (rs1800795) SNP in IL6 was determined by PCR-RFLP. There were estimated plasma total and high molecular weight adiponectin (HMWA), insulin, leptin, osteoprotegerin (OPG), retinol-binding protein-4 (RBP4), fetuin-A, vaspin levels etc. by ELISA in the basal state and after the treatment. Insulin resistance (IR) was assessed using homeostasis model assessment (HOMA-IR) algorithm. Unpaired Student's t -test, Fisher's test and Chi 2 test were used. Data are expressed as mean±SEM or median (25;75). Results Comparing with controls ( n =21) T2D patients were characterized by significant ( P P Conclusions Our data show the role of +174 G>C IL6 SNP in omega-3 fatty acid therapeutic efficacy forming in type 2 diabetics with respect to new cardiovascular risk factors (adipocytokines, antioxidant protection) with the indication of GG-genotype as the most reactive. These results confirm the perspective of pharmacogenetics as a basis for personalized therapy with the predicted effect of pharmacological intervention.